These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 1740387)

  • 21. A Policy-Driven Perspective on Rising Drug Costs in Dermatology.
    Nguyen HP; Forman HP
    JAMA Dermatol; 2016 Jun; 152(6):625-6. PubMed ID: 27008060
    [No Abstract]   [Full Text] [Related]  

  • 22. American pharmaceutical prices.
    Alagona P
    Pharos Alpha Omega Alpha Honor Med Soc; 2002; 65(4):58. PubMed ID: 12592980
    [No Abstract]   [Full Text] [Related]  

  • 23. Pharmaceutical companies' variation of drug prices within and among countries can improve long-term social well-being.
    Lichtenberg FR
    Health Aff (Millwood); 2011 Aug; 30(8):1539-44. PubMed ID: 21821571
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmaceutical industry.
    Lewis L
    State Health Care Am; 1994; ():23-7. PubMed ID: 10133845
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of the German reference drug program on ex-factory prices of prescription drugs: a panel data approach.
    Augurzky B; Göhlmann S; Gress S; Wasem J
    Health Econ; 2009 Apr; 18(4):421-36. PubMed ID: 18677725
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Drug price controls will cripple research and development, pharmaceutical executives tell Congress.
    Am J Hosp Pharm; 1994 May; 51(9):1132, 1135-6, 1139. PubMed ID: 8042629
    [No Abstract]   [Full Text] [Related]  

  • 27. Are drug too expensive in Canada? No.
    Williams R; Marion J
    Can Fam Physician; 2006 May; 52():573-6, 578-81. PubMed ID: 16739822
    [No Abstract]   [Full Text] [Related]  

  • 28. The pharmaceutical industry--to whom is it accountable?
    Summers WK; Driscoll J; Orient JM
    N Engl J Med; 2000 Nov; 343(19):1416; discussion 1417. PubMed ID: 11183883
    [No Abstract]   [Full Text] [Related]  

  • 29. The Economics of Indication-Based Drug Pricing.
    Chandra A; Garthwaite C
    N Engl J Med; 2017 Jul; 377(2):103-106. PubMed ID: 28700848
    [No Abstract]   [Full Text] [Related]  

  • 30. Prescription drug manufacturers get warning on prices.
    Margolis RE
    Healthspan; 1993 Mar; 10(3):19-20. PubMed ID: 10125344
    [No Abstract]   [Full Text] [Related]  

  • 31. The cost of prescription drugs: rising concerns over equity, fairness and access to essential care.
    Work DR; Domino ME
    N C Med J; 2003; 64(6):270-4. PubMed ID: 14983614
    [No Abstract]   [Full Text] [Related]  

  • 32. Examining the link between price regulation and pharmaceutical R&D investment.
    Vernon JA
    Health Econ; 2005 Jan; 14(1):1-16. PubMed ID: 15386673
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmaceutical manufacturers ... leaving tradition behind and forging new managed care alliances.
    Barnett AA
    State Health Care Am; 1995; ():41-6. PubMed ID: 10168072
    [No Abstract]   [Full Text] [Related]  

  • 34. Managed care cost containment involving prescription drugs. American Medical Association, Council on Ethical and Judicial Affairs.
    Food Drug Law J; 1998; 53(1):25-34. PubMed ID: 11795334
    [No Abstract]   [Full Text] [Related]  

  • 35. After years of steady growth, winds of restraint blowing on prescription-drug industry.
    Robinson A
    CMAJ; 1995 Jul; 153(1):85-8. PubMed ID: 7796380
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Discount for only one drug of the same group leads to impaired health care quality].
    Bergström R
    Lakartidningen; 2006 Feb 8-14; 103(6):387-8; discussion 388. PubMed ID: 16536044
    [No Abstract]   [Full Text] [Related]  

  • 37. The pharmaceutical industry--to whom is it accountable?
    Rightor N
    N Engl J Med; 2000 Nov; 343(19):1416; discussion 1417. PubMed ID: 11183882
    [No Abstract]   [Full Text] [Related]  

  • 38. Doubts emerge about drug industry mergers.
    Bus Health; 1994 Nov; 12(11):53-4, 56, 61. PubMed ID: 10138536
    [No Abstract]   [Full Text] [Related]  

  • 39. Market-based licensing for HPV vaccines in developing countries.
    Outterson K; Kesselheim AS
    Health Aff (Millwood); 2008; 27(1):130-9. PubMed ID: 18180488
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The importance of being first: evidence from Canadian generic pharmaceuticals.
    Hollis A
    Health Econ; 2002 Dec; 11(8):723-34. PubMed ID: 12457372
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.